<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T21:05:27Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/nkfw9k2chm.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/nkfw9k2chm.1</identifier>
                <datestamp>2025-03-18T15:30:34Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Ong, Michael</dc:creator>
    <dc:title>Association between acneiform eruption grade and survival outcomes in metastatic colorectal cancer patients treated with epidermal growth factor receptor inhibitors</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>Supplementary figures for Ong et al. Association between acneiform eruption grade and survival outcomes in metastatic colorectal cancer patients treated with epidermal growth factor receptor inhibitors.

Supplementary figure 1: Progression-free survival in mCRC patients on EGFRis.
Supplementary figure 1 legend: EGFRis, epidermal growth factor receptor inhibitors; g0, grade 0 rash; g1, grade 1 rash; g2/g3, grade 2/grade 3 rash; mCRC, metastatic colorectal cancer
Median progression-free survival for grades 0, 1, and 2/3 rashes were 3.0, 5.5, and 5.1 months, respectively (p&lt;0.001).

Supplementary figure 2. Overall survival in mCRC patients on EGFRis.
Supplementary figure 2 legend: EGFRis, epidermal growth factor receptor inhibitors; g0, grade 0 rash; g1, grade 1 rash; g2/g3, grade 2/grade 3 rash; mCRC, metastatic colorectal cancer
Median overall survival for grades 0, 1, and 2/3 rashes were 6.8, 18.0, and 18.1 months, respectively (p&lt;0.001).</dc:description>
    <dc:subject>Dermatology</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/nkfw9k2chm.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/nkfw9k2chm.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/nkfw9k2chm</dc:relation>
    <dc:date>2025-03-18T15:30:34Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
